Abbie Celniker
Partner at Third Rock Ventures
Massachusetts
Writes $100K – $5M checks · typically $1.5M
About
A biotech executive with over 30 years in senior R&D and leadership roles, she joined Third Rock Ventures in 2016, where she focuses on the formation, development, and strategy of portfolio companies. She previously served as CEO of Eleven Biotherapeutics and Taligen Therapeutics, and held senior roles at Novartis, Millennium Pharmaceuticals, and Wyeth.
Invests in
BiotechMedical Devices
Deals · 7
Abata TherapeuticsBoard seat
via Third Rock Ventures · filed Jun 2022 · $95M raise
Cedilla Therapeutics, Inc.Board seat
via Third Rock Ventures · filed Oct 2021 · $82.6M raise
Goldfinch BioPharmaBoard seat
via Third Rock Ventures · filed Jul 2020
PanOpticaBoard seat
via Third Rock Ventures · filed Apr 2019 · $47.3M raise
Rheos MedicinesBoard seat
via Third Rock Ventures · filed Nov 2018
Eleven BiotherapeuticsBoard seat
via Third Rock Ventures · filed Apr 2018 · $996K raise
ImaginabBoard seat
via Third Rock Ventures · filed Apr 2016 · $9.5M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Third Rock Ventures
Network11
Investors connected to Abbie in public investor directories — a warm-intro map.